These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31300214)

  • 1. Tumor pseudoprogression during nivolumab immunotherapy for lung cancer.
    Mayoral M; Castañer E; Gallardo X; Andreu M; Dalmau E; Garcia Y
    Radiologia (Engl Ed); 2019; 61(6):498-505. PubMed ID: 31300214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiologic Pseudoprogression during Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    Katz SI; Hammer M; Bagley SJ; Aggarwal C; Bauml JM; Thompson JC; Nachiappan AC; Simone CB; Langer CJ
    J Thorac Oncol; 2018 Jul; 13(7):978-986. PubMed ID: 29738824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pseudoprogression in Previously Treated Patients with Non-Small Cell Lung Cancer Who Received Nivolumab Monotherapy.
    Fujimoto D; Yoshioka H; Kataoka Y; Morimoto T; Hata T; Kim YH; Tomii K; Ishida T; Hirabayashi M; Hara S; Ishitoko M; Fukuda Y; Hwang MH; Sakai N; Fukui M; Nakaji H; Morita M; Mio T; Yasuda T; Sugita T; Hirai T
    J Thorac Oncol; 2019 Mar; 14(3):468-474. PubMed ID: 30468872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case series.
    Kanazu M; Edahiro R; Krebe H; Nishida K; Ishijima M; Uenami T; Akazawa Y; Yano Y; Yamaguchi T; Mori M
    Thorac Cancer; 2018 Dec; 9(12):1782-1787. PubMed ID: 30328672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of morphological characteristics assessed by CT scan in patients with non-small cell lung cancer treated with nivolumab.
    Minemura H; Moriya H; Imai H; Sugiyama T; Yamada Y; Higuchi M; Kaira K; Ozaki Y; Kanazawa K; Yokouchi H; Kasai T; Kaburagi T; Suzuki H; Minato K; Shibata Y
    Thorac Cancer; 2020 Dec; 11(12):3521-3527. PubMed ID: 33044045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thoracic Imaging of Non-Small Cell Lung Cancer Treated With Anti-programmed Death Receptor-1 Therapy.
    Hammer M; Bagley S; Aggarwal C; Bauml J; Nachiappan AC; Simone CB; Langer C; Katz SI
    Curr Probl Diagn Radiol; 2019; 48(2):142-147. PubMed ID: 29573843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Serum Biomarker CEA and Ca-125 as Immunotherapy Response Predictors in Metastatic Non-small Cell Lung Cancer.
    Clevers MR; Kastelijn EA; Peters BJM; Kelder H; Schramel FMNH
    Anticancer Res; 2021 Feb; 41(2):869-876. PubMed ID: 33517292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression.
    Ricciuti B; Genova C; Bassanelli M; De Giglio A; Brambilla M; Metro G; Baglivo S; Dal Bello MG; Ceribelli A; Grossi F; Chiari R
    Clin Lung Cancer; 2019 May; 20(3):178-185.e2. PubMed ID: 30910574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Well-controlled pleural effusion indicated pseudoprogression after immunotherapy in lung cancer: A case report.
    Liu G; Chen T; Li R; Zhu L; Liu D; Ding Z
    Thorac Cancer; 2018 Sep; 9(9):1190-1193. PubMed ID: 29978949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diffuse pseudoprogression in a patient with metastatic non-small-cell lung cancer treated with Nivolumab.
    Curioni-Fontecedro A; Ickenberg C; Franzen D; Rogler G; Burger IA; van den Broek M
    Ann Oncol; 2017 Aug; 28(8):2040-2041. PubMed ID: 28838208
    [No Abstract]   [Full Text] [Related]  

  • 11. Prognostic and predictive value of histogram analysis in patients with non-small cell lung cancer refractory to platinum treated by nivolumab: A multicentre retrospective study.
    Ravanelli M; Agazzi GM; Milanese G; Roca E; Silva M; Tiseo M; Rondi P; Baggi A; Ganeshan B; Muri M; Panni S; Botti C; Sverzellati N; Maroldi R; Berruti A; Farina D
    Eur J Radiol; 2019 Sep; 118():251-256. PubMed ID: 31439251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors.
    Tozuka T; Kitazono S; Sakamoto H; Yoshida H; Amino Y; Uematsu S; Yoshizawa T; Hasegawa T; Uchibori K; Yanagitani N; Horiike A; Horai T; Seike M; Gemma A; Nishio M
    BMC Cancer; 2020 Mar; 20(1):207. PubMed ID: 32164651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis.
    Giaj Levra M; Cotté FE; Corre R; Calvet C; Gaudin AF; Penrod JR; Grumberg V; Jouaneton B; Jolivel R; Assié JB; Chouaïd C
    Lung Cancer; 2020 Feb; 140():99-106. PubMed ID: 31911324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
    Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
    BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Granulation Tissue-induced Pseudo-relapse During Nivolumab Treatment in Advanced Non-small Cell Lung Cancer.
    Ando C; Ichihara E; Kano H; Iwamoto Y; Hirabae A; Nakasuka T; Maeda Y; Kiura K
    In Vivo; 2019; 33(6):2113-2115. PubMed ID: 31662545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
    Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes of nivolumab in patients with advanced non-small cell lung cancer in real-world practice, with an emphasis on hyper-progressive disease.
    Kim SH; Choi CM; Lee DH; Kim SW; Yoon S; Kim WS; Ji W; Lee JC
    J Cancer Res Clin Oncol; 2020 Nov; 146(11):3025-3036. PubMed ID: 32583235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients.
    Sarocchi M; Grossi F; Arboscello E; Bellodi A; Genova C; Dal Bello MG; Rijavec E; Barletta G; Rossi G; Biello F; Ghigliotti G; Canepa M; Mussap M; Brunelli C; Spallarossa P
    Oncologist; 2018 Aug; 23(8):936-942. PubMed ID: 29567824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiographic features and poor prognostic factors of interstitial lung disease with nivolumab for non-small cell lung cancer.
    Saito Y; Sasaki S; Oikado K; Tominaga J; Sata M; Sakai F; Kato T; Iwasawa T; Kenmotsu H; Kusumoto M; Baba T; Endo M; Fujiwara Y; Sugiura H; Yanagawa N; Ito Y; Sakamoto T; Ohe Y; Kuwano K
    Cancer Sci; 2021 Apr; 112(4):1495-1505. PubMed ID: 33098725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab.
    Bouhlel L; Doyen J; Chamorey E; Poudenx M; Ilie M; Gal J; Guigay J; Benzaquen J; Marquette CH; Berthet JP; Mouroux J; Schiappa R; Padovani B; Hofman P; Otto J
    Bull Cancer; 2020 Sep; 107(9):946-958. PubMed ID: 32646604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.